H. Lundbeck A/s

Other

Cephalon, Inc.

House of Prince A/s

Intelligent Systems A/s

Bekey A/s

Haleh Ahmadian

Henrik Pedersen

Peter Brosen

Christina Suteu

Olivier Dapremont

Usha Nair

Sebastian P. Assenza

Shankar Hariharan

Fiona Geiser

Ole Nielsen

Heidi Lopez De Diego

Michael Harold Rock

Mark Howells

Hans Petersen

Robert Dancer

Benny Bang-Andersen

Ken Liljegren

Allan Carsten Dahl

Henrik Svane

Helle Eliasen

Lone Munch Ringgard

Kim Lasse Christensen

Lars Ole Lyngso

Sherry Collier

Anders Buur

Rikke Eva Humble

Troels Volsgaard Christensen

Rikke E Humble

Michael Bech Sommer

Niels Mørk

Sebastian P Assenza

Lars Ole Lyngsø

Ebbe Andersen

Niki Nicolas Grigoriou

Morten Nielsen

Geoffrey Cox

James Lee

Sven Wagner

Per Holm

A transport and storage system, for servicing of a number of treatment and care areas in a hospital, is provided. The system connects each treatment and care area to a first transport route reserved for transport of clean goods to or from the treatment and care area, and a second transport route reserved for transport of non-clean goods to or from the treatment and care area, the first and second transport routes being separated. In the system, a partition is provided between the transport routes and the treatment and care areas, with a lock gate being included in the partition. The transport routes include a conveyor to containers, with the conveyor being connected to the lock gate and the containers having a container brim enclosable by an opening in the lock gate.

Transport and storage system for servicing of a number of treatment and care areas in a hospital and method for operation hereof

Described are crystalline forms of the pharmaceutical compound '[9S-(9&#x3b1;,10&#x3b2;,12&#x3b1;)]-5,16-Bis[(ethylthio)methyl]-2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-9,12-epoxy-1H-diindolo[1,2,3-fg:3',2&#x2032;,1&#x2032;-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid methyl ester', as well as methods for their use and preparation.

Crystalline forms of a pharmaceutical compound

The invention relates to a dispenser apparatus for goods, said apparatus comprising a storage unit () for storing goods in a number of storage passages (), a unit () for conveying one or more goods from the storage unit () to a conveyor unit (), said conveyor unit () conveying, via an air pressure, goods to a dispensing station, wherein the storage passages () of the storage unit () forms an angle to the horizontal which is larger than or smaller than 90&#xb0;, and wherein the unit () in the form of a fetcher mechanism comprises one or more ejectors for pushing one or more goods conveyed into one or more transfer chambers () into a conveyor pipe (). The invention also comprises a method of dispensing goods, wherein the method comprises receipt of data representing selection of at least one item (); and dispensing from a dispenser apparatus of said at least one item, if said at least one item is in stock in said apparatus for dispensing, and if said dispenser apparatus has received data representing a recording of said at least one item and/or recording of a payment made in respect of said at least one item ().

Apparatus and a method and a system for dispensing goods

Methods for the preparation of 4-((1R,3S)-6-Chloro-3-phenylindan-1-yl)-1,2,2-trimethylpiperazine and salts thereof are described.

Processes for 4-((1R,35)-6-Chloro-3-phenylindan-1-yl)-1,2,2-trimethylpiperazine or a salt thereof

Described are crystalline forms of the pharmaceutical compound '[9S-(9&#x3b1;,10&#x3b2;,12&#x3b1;)]-5,16-Bis[(ethylthio)methyl]-2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-9, 12-epoxy-1H-diindolo[1,2,3-fg:3',2&#x2032;,1&#x2032;-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid methyl ester', as well as methods for their use and preparation.

4-((1R,3S)-6-Chloro-3-phenylindan-1-yl)-1,2,2-trimethylpiperazine hydrogen malonate salt and pharmaceutical comprising and uses of the same, including for the treatment of schizophrenia and other psychotic disorders are described.

Malonate salt of 4-((1R,3S)-6-chloro-3-phenylindan-1-yl)-1,2,2-trimethylpiperazine and uses of same

The present invention relates to the crystalline base of the well known antidepressant drug escitalopram, S-1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-5-isobenzofurancarbonitrile, formulations of said base, a process for the preparation of purified salts of escitalopram, such as the oxalate, using the base, the salts obtained by said process and formulations containing such salts, and a process for the preparation of purified escitalopram free base or salts of escitalopram, such as the oxalate, using the hydrobromide, the salts obtained by said process and formulations containing such salts. Finally the present invention relates to an orodispersible tablet having a hardness of at least 22 N and an oral-disintegration time of less than 120 s and comprising an active pharmaceutical ingredient adsorbed onto a water soluble filler wherein the active pharmaceutical ingredient has a melting point in the range of 40-100&#xb0; C., as well as a method for making such an orodispersible tablet.

Crystalline base of escitalopram and orodispersible tablets comprising escitalopram base

4-((1R,3S)-6-Chloro-3-phenylindan-1-yl)-1,2,2-trimethylpiperazine hydrogen succinate, pharmaceutical compositions containing the salt and the medical use thereof, including for the treatment of schizophrenia and other psychotic disorders. Also described are methods for the preparation of 4-((1R,3S)-6-Chloro-3-phenylindan-1-yl)-1,2,2-trimethylpiperazine and medical uses thereof.

Hydrogen succinate salts of trans-4-((1R, 3S)-6-chloro-3-phenylindan-1-YL)-1,2,2-trimethylpiperazine and the use as a medicament

The present invention relates to the crystalline base of the well known antidepressant drug escitalopram, S-1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-5-isobenzo-furancarbonitrile, formulations of said base, a process for the preparation of purified salts of escitalopram, such as the oxalate, using the base, the salts obtained by said process and formulations containing such salts, and a process for the preparation of purified escitalopram free base or salts of escitalopram, such as the oxalate, using the hydrobromide, the salts obtained by said process and formulations containing such salts. Finally the present invention relates to an orodispersible tablet having a hardness of at least 22 N and an oral-disintegration time of less than 120 s and comprising an active pharmaceutical ingredient adsorbed onto a water soluble filler wherein the active pharmaceutical ingredient has a melting point in the range of 40-100&#xb0; C., as well as a method for making such an orodispersible tablet.

The invention relates to a process for the preparation of racemic citalopram free base or an acid addition salt thereof and/or R- or S-citalopram as the free base or an acid addition salt thereof by separation of a mixture of R- and S-citalopram with more than 50% of one of the enantiomers into a fraction consisting of racemic citalopram and/or a fraction of S-citalopram or R-citalopram characterized in that i) citalopram is precipitated from a solvent as the free base or as an acid addition salt thereof; ii) the precipitate formed is separated from the mother liquor; iia) if the precipitate is crystalline it is optionally recrystallised one or more times to form racemic citalopram, and then optionally converted into an acid addition salt thereof; iib) if the precipitate is not crystalline, steps i) and ii) are optionally repeated until a crystalline precipitate is obtained and the crystalline precipitate is recrystallised one or more times to form racemic citalopram, and then optionally converted into an acid addition salt thereof; iii) the mother liquor is optionally subjected to further purification and S-citalopram or R-citalopram is isolated from the mother liquor and optionally converted into an addition salt thereof.

Process for the preparation of racemic citalopram and/or S-or R-citalopram by separation of a mixture of R-and S-citalopram

The present invention relates to a hydrohalogenide of 1'-[4-[1-(4-fluorophenyl)-1H-indole-3-yl]-1-butyl]-spiro[isobenzofuran-1(3H),4&#x2032;-piperidine], pharmaceutical compositions containing the acid addition salts and the use thereof for the treatment of psychic and neurological disorders.

1'-[4-[1-(4-fluorophenyl)-1H-indole-3-yl]-1-butyl]-spiro[isobenzofuran-1(3H),4&#x2032;-piperidine] hydrohalogenides

Apparatus for controlling a valve

Data communication system of the field bus type with a twin lead for

Growing community of inventors

Valby, Denmark

Ole Nielsen